COMMUNIQUÉS West-GlobeNewswire

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
04/12/2025
Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer’s disease by up to 8.3 years in low-amyloid group who started treatment at an early [...]
Mesoblast Participation at Piper Sandler Conference
04/12/2025
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its participation at the Piper Sandler 37 [...]
Regentis Biomaterials Ltd. Announces Pricing of Initial Public Offering
04/12/2025
Herzliya, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair [...]
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
04/12/2025
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistance The Phase 1 [...]
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
04/12/2025
ALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of peripheral nerve function [...]
Hapbee Appoints Hasan Shahid to Board of Directors to Strengthen Capital Markets & Strategic Growth Capabilities
04/12/2025
Seasoned technologist, investor, and capital markets leader joins Hapbee’s Board VANCOUVER, British Columbia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Hapbee Technologies, Inc. (TSXV: HAPB ; OTCQB: HAPBF ; FWB: HA1 ) (“ Hapbee [...]
The Hemp Doctor Introduces THCA Flower Subscription Box — Monthly Curated Rotating Strains, Pre-Rolls & Extras
04/12/2025
MOORESVILLE, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Hemp Doctor, one of America’s leading hemp brands, announces the launch of its Fresh Bloom THCA Flower Subscription Box —delivering a curated monthly lineup of [...]
Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes
03/12/2025
Media Release COPENHAGEN, Denmark; December 3, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) have closed their previously [...]
HealthEquity Reports Third Quarter Ended October 31, 2025 Financial Results
03/12/2025
Highlights of the third quarter include: Revenue increased 7% to $322.2 million. Net income per diluted share rose to $0.59 from $0.06 one year ago, and non-GAAP net income per diluted share increased 29% to $1.01. [...]
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/12/2025
BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025
03/12/2025
Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage [...]
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03/12/2025
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on December 1, 2025, the [...]
Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update
03/12/2025
– Fourth quarter fiscal 2025 revenue up 5.9% to $138.1 million – Fiscal 2025 revenue increased 4.5% to $513.0 million – Fourth quarter fiscal 2025 operating loss decreased 48.5% to $6.8 million – Fiscal 2025 operating [...]
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
03/12/2025
WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies [...]
Soleno Therapeutics Announces the Passing of Board Member William G. Harris
03/12/2025
REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today regrets to [...]
Picard Medical, Inc. and SynCardia Systems LLC CEO to Present at CSI Focus D-HF 2025 in Frankfurt, Germany
03/12/2025
TUCSON, Ariz., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
03/12/2025
ZUG, Switzerland, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment Notification of managers' [...]
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
03/12/2025
ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]
Mural Oncology Announces Sanction of the Scheme by the High Court
03/12/2025
WALTHAM, Mass. and DUBLIN, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“ Mural ”) announces that the High Court of Ireland has today sanctioned the scheme of arrangement between Mural and its [...]

Pages